The buzz surrounding the ESMO 2026 conference reached a peak as Georgina Long from the Melanoma Institute Australia presented results from the intismeran INTerpath-001 study. The auditorium teemed with attendees eager for insights, creating an atmosphere of anticipation. Despite a preliminary data leak that tempered the initial excitement, Long’s presentation garnered extended applause, reflecting the audience's engagement with the findings.
The study reported a 42% reduction in disease recurrence and an impressive 38% improvement in distant metastasis-free survival. Long characterized these findings as establishing a “new benchmark for adjuvant treatment of melanoma,” signifying a pivotal moment in personalized cancer therapy. Following her presentation, Inge Marie Svane from the University of Copenhagen provided a measured perspective, expressing that, while the results were compelling, critical questions lingered. Notably, the discussions revolved around whether intismeran would confer a significant survival advantage and the underlying mechanisms contributing to the vaccine's effectiveness — whether attributed to specific neoantigen targeting or a broader immune boost characteristic of mRNA-based vaccines.
Svane also addressed treatment strategies for the approximately 40% of higher-risk patients involved in the study, underlining this as an area of contention with substantial commercial implications. Should intismeran receive approval, it would enter a competitive market against neoadjuvant immunotherapy approaches, raising unanswered questions about optimal patient management.
A significant portion of the dialogue surrounding the Merck and Moderna collaboration focused on the validity of the data and the broader implications of individualized cancer treatments. Toni Choueiri from Dana-Farber Cancer Institute highlighted a critical issue: the pervasive mistrust and misinformation regarding mRNA technologies. He emphasized that skepticism toward mRNA-based vaccines for infectious diseases has spilled over into oncology, making it a challenge for healthcare providers.
Choueiri shared concerning statistics that indicate widespread misconceptions about mRNA technology, including erroneous beliefs about its ability to alter human DNA. He argued that such misconceptions could negatively impact the reception of any mRNA vaccine, notably those designed for cancer treatment. Efforts to rebrand cancer vaccines, simplifying terminology to personalized neoantigen therapy, aim to mitigate these fears.
Stéphane Bancel, CEO of Moderna, expressed optimism that demonstrating the efficacy of an mRNA treatment in cancer could enhance public perception, reinforcing the concept that mRNA is a natural component of human biology that plays a vital role in health.
The conference also spotlighted the combination of Amgen’s Imdelltra and AstraZeneca’s Imfinzi, which, as presented in the DeLLphi-305 study, showed promising results for patients with extensive-stage small cell lung cancer. The dual therapy yielded a median overall survival of just over 21 months, significantly higher than the 13-month median observed in patients receiving Imfinzi alone. Notably, this regimen was associated with a 58% reduction in mortality risk.
Attendance was energized as reports of a standing ovation echoed in the room. However, adverse events were recorded, notably cytokine release syndrome, impacting nearly half of patients in the combination therapy arm, although most cases were classified as mild to moderate. With 563 patients enrolled, all had experienced disease stability following first-line immunotherapy, setting a new benchmark for maintenance therapy in this challenging cancer type.
Jacob Sands from Dana-Farber Cancer Institute described the observed survival curve separation as extraordinary, a phenomenon not typically seen in small cell lung cancer treatments. He advocated for the therapy as a strong option, leaving no ambiguity regarding its potential benefits for eligible patients.
Lastly, Astrazeneca presented findings from its Phase 3 VOLGA study, revealing that the neoadjuvant use of Imfinzi with Pfizer’s Padcev led to a 42% reduction in mortality risk and a 49% decrease in disease progression when compared to surgery alone. Despite these positive outcomes, they did not quite meet the expectations set by existing standard care protocols.
At the two-year mark, 63% of patients receiving the Imfinzi-Padcev combination remained alive without progression versus 45% in the surgical group. However, overall survival rates were similarly higher for the treatment group, with 78% survival compared to 69% for surgery alone. Despite promising data, the results have not convincingly surpassed the efficacy seen in alternative therapies such as Merck’s Keytruda combined with Padcev, which previously demonstrated a 50% reduction in death risk and a 60% decline in tumor progression risk.